We have located links that may give you full text access.
Permanent brachytherapy as salvage treatment for recurrent prostate cancer.
Urology 1999 November
OBJECTIVES: To determine the prostate-specific antigen (PSA)-based freedom from second failure, survival, and morbidity of permanent brachytherapy as salvage treatment for men for whom primary external beam irradiation of prostate cancer failed.
METHODS: A retrospective review was performed on 17 consecutive men seen and treated with permanent brachytherapy for recurrent adenocarcinoma of the prostate from February 1989 to May 1994. Patients had been treated with a median of 63.3 Gy and presented with progressive local disease 23 to 146 months later (median 54). After a staging evaluation documenting no distant disease, all received permanent implantation of iodine-125 for 120 Gy (15 patients) or palladium-103 for 90 Gy (2 patients) using a transperineal ultrasound-guided technique. All doses were calculated before TG-43. Progression after brachytherapy was defined according to the ASTRO Consensus Conference definition. All results are reported as Kaplan-Meier actuarial 5-year results.
RESULTS: The 5-year actuarial freedom from second relapse was 53%. Both PSA and Gleason score appear to be prognostic factors, although both failed to reach statistical significance. Patients with a PSA 10 ng/mL or less at the time of salvage therapy had a freedom from second relapse rate of 67% compared with 25% for men with a PSA greater than 10 ng/mL (P = 0. 15). Those with low-grade tumor at the time of salvage therapy had an 83% freedom from second relapse rate compared with 30% for those with high-grade cancer (P = 0. 12). With 93% alive at 5 years, no significant difference was seen in survival on the basis of these prognostic groups. Acute and transient toxicity were readily managed and indistinguishable from that reported for previously unirradiated patients. Long-term complications were limited to a 24% risk of incontinence at 5 years.
CONCLUSIONS: Ultrasound-guided transperineal brachytherapy is an effective second-line therapy for patients for whom external beam irradiation has failed. Early intervention may be valuable when the PSA is less than 10 ng/mL. The risk of incontinence is significant, and patients must be individually counseled.
METHODS: A retrospective review was performed on 17 consecutive men seen and treated with permanent brachytherapy for recurrent adenocarcinoma of the prostate from February 1989 to May 1994. Patients had been treated with a median of 63.3 Gy and presented with progressive local disease 23 to 146 months later (median 54). After a staging evaluation documenting no distant disease, all received permanent implantation of iodine-125 for 120 Gy (15 patients) or palladium-103 for 90 Gy (2 patients) using a transperineal ultrasound-guided technique. All doses were calculated before TG-43. Progression after brachytherapy was defined according to the ASTRO Consensus Conference definition. All results are reported as Kaplan-Meier actuarial 5-year results.
RESULTS: The 5-year actuarial freedom from second relapse was 53%. Both PSA and Gleason score appear to be prognostic factors, although both failed to reach statistical significance. Patients with a PSA 10 ng/mL or less at the time of salvage therapy had a freedom from second relapse rate of 67% compared with 25% for men with a PSA greater than 10 ng/mL (P = 0. 15). Those with low-grade tumor at the time of salvage therapy had an 83% freedom from second relapse rate compared with 30% for those with high-grade cancer (P = 0. 12). With 93% alive at 5 years, no significant difference was seen in survival on the basis of these prognostic groups. Acute and transient toxicity were readily managed and indistinguishable from that reported for previously unirradiated patients. Long-term complications were limited to a 24% risk of incontinence at 5 years.
CONCLUSIONS: Ultrasound-guided transperineal brachytherapy is an effective second-line therapy for patients for whom external beam irradiation has failed. Early intervention may be valuable when the PSA is less than 10 ng/mL. The risk of incontinence is significant, and patients must be individually counseled.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app